Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy
TLR4 agonists have been proposed as immunotherapeutics in cancer. Here, the authors show the TLR4-dependent adjuvant effect of FimH, an E. coli adhesin, in promoting dendritic cell mediated-T cell activation and response to immune checkpoint blockade in preclinical cancer models.
Saved in:
Main Authors: | Wei Zhang, Li Xu, Hae-Bin Park, Juyoung Hwang, Minseok Kwak, Peter C. W. Lee, Guang Liang, Xiaoyan Zhang, Jianqing Xu, Jun-O Jin |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2020
|
Subjects: | |
Online Access: | https://doaj.org/article/ed2a29d550e746acad1fd481acb4d24e |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Catch-bond mechanism of the bacterial adhesin FimH
by: Maximilian M. Sauer, et al.
Published: (2016) -
FimH-based display of functional eukaryotic proteins on bacteria surfaces
by: Markus Chmielewski, et al.
Published: (2019) -
Point mutations in FimH adhesin of Crohn's disease-associated adherent-invasive Escherichia coli enhance intestinal inflammatory response.
by: Nicolas Dreux, et al.
Published: (2013) -
Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect
by: Sara Nava, et al.
Published: (2021) -
Course of the vertical portion of the lower lacrimal canaliculus
by: Hirohiko Kakizaki, et al.
Published: (2008)